Squarepoint Ops LLC Grows Stock Position in Dynavax Technologies Corporation $DVAX

Squarepoint Ops LLC raised its holdings in shares of Dynavax Technologies Corporation (NASDAQ:DVAX) by 222.3% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 435,577 shares of the biopharmaceutical company’s stock after acquiring an additional 300,421 shares during the quarter. Squarepoint Ops LLC owned approximately 0.37% of Dynavax Technologies worth $4,321,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. State of Wyoming purchased a new stake in shares of Dynavax Technologies in the second quarter valued at about $304,000. Hudson Bay Capital Management LP increased its stake in shares of Dynavax Technologies by 46.4% during the 2nd quarter. Hudson Bay Capital Management LP now owns 541,600 shares of the biopharmaceutical company’s stock worth $5,373,000 after purchasing an additional 171,700 shares in the last quarter. Tower Research Capital LLC TRC raised its position in shares of Dynavax Technologies by 319.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 16,239 shares of the biopharmaceutical company’s stock worth $161,000 after purchasing an additional 12,371 shares during the last quarter. E Fund Management Co. Ltd. lifted its stake in Dynavax Technologies by 17.9% in the 2nd quarter. E Fund Management Co. Ltd. now owns 18,113 shares of the biopharmaceutical company’s stock valued at $180,000 after buying an additional 2,752 shares in the last quarter. Finally, Man Group plc lifted its stake in Dynavax Technologies by 925.5% in the 2nd quarter. Man Group plc now owns 447,847 shares of the biopharmaceutical company’s stock valued at $4,443,000 after buying an additional 404,175 shares in the last quarter. Institutional investors and hedge funds own 96.96% of the company’s stock.

Dynavax Technologies Trading Up 0.5%

Shares of DVAX opened at $10.85 on Tuesday. Dynavax Technologies Corporation has a fifty-two week low of $9.20 and a fifty-two week high of $14.63. The company has a market capitalization of $1.27 billion, a PE ratio of -29.32 and a beta of 0.88. The stock has a fifty day moving average of $10.66 and a two-hundred day moving average of $10.43. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.94 and a current ratio of 7.62.

Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported $0.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.07. The business had revenue of $94.88 million for the quarter, compared to analysts’ expectations of $94.00 million. Dynavax Technologies had a positive return on equity of 7.18% and a negative net margin of 13.13%. As a group, analysts forecast that Dynavax Technologies Corporation will post 0.32 EPS for the current year.

Wall Street Analyst Weigh In

DVAX has been the subject of several recent research reports. Weiss Ratings reissued a “sell (d)” rating on shares of Dynavax Technologies in a research report on Wednesday, October 8th. JMP Securities reaffirmed a “market outperform” rating and set a $32.00 price objective on shares of Dynavax Technologies in a research note on Friday, August 22nd. Three research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $24.33.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.